Haematologica
HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Litzow, M.
Right arrow Articles by Tallman, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Litzow, M.
Right arrow Articles by Tallman, M.
Haematologica, Vol 91, Issue 8, 1105-1108
Copyright © 2006 by Ferrata Storti Foundation

Clinical Trial, Phase II

A phase II trial of arsenic trioxide for relapsed and refractory acute lymphoblastic leukemia

MR Litzow, S Lee, JM Bennett, GW Dewald, RE Gallagher, V Jain, EM Paietta, J Racevskis, Rousey SR, JJ Mazza, and MS Tallman

Division of Hematology, Mayo Clinic College of Medicine, 200 First St. S.W., Rochester, MN 55905, USA. litzow.mark@mayo.edu

We designed a phase II trial of arsenic trioxide (AT) for the treatment of relapsed and refractory acute lymphoblastic leukemia (ALL). The dose administered was 0.25 mg/kg/day intravenously for 5-7 days per week for up to 60 days. Of 11 patients eligible, eight had B-cell and three T-cell ALL and two were Philadelphia chromosome-positive. The median duration of therapy was 21 days (range 7-28). One patient died of an infection. There were no responses. Ten patients have died. The median survival was 3.2 months (range 1.2-4.1). We conclude that AT is not active in the treatment of ALL.


This article has been cited by other articles:


Home page
 BloodHome page
B. C. Bornhauser, L. Bonapace, D. Lindholm, R. Martinez, G. Cario, M. Schrappe, F. K. Niggli, B. W. Schafer, and J.-P. Bourquin
Low-dose arsenic trioxide sensitizes glucocorticoid-resistant acute lymphoblastic leukemia cells to dexamethasone via an Akt-dependent pathway
Blood, September 15, 2007; 110(6): 2084 - 2091.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK TABLE OF CONTENTS ARCHIVE SUBSCRIPTIONS
Copyright © 2006 by the Ferrata Storti Foundation.